Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Vedotin With Osimertinib for EGFR Mutated NSCLC With c-MET Overexpression
NCT07323641Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of telisotuzumab vedotin in non-small cell lung cancer (NSCLC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Feb 2026; status: recruiting.
02
Drugs
telisotuzumab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07323641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07323641.